Hetty E Carraway,Daniel A Pollyea,Eytan M Stein
Hetty E Carraway
The advances and progress in the understanding and management of acute leukemia and myelodysplasia continue to occur at an exponential rate. While this has led to more therapy options, clinicians and researchers are now facing more challeng...
Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant? [0.03%]
所有急性淋巴细胞白血病的CAR-T治疗都应与异体干细胞移植结合吗？
Alejandro Marinos,Helen E Heslop
Alejandro Marinos
Autologous T cells genetically modified with a CD19 chimeric antigen receptor are an effective therapy for children and adults with relapsed or refractory acute lymphoblastic leukemia with initial response rates ranging from 70 to 85%. Unfo...
Mikkael A Sekeres
Mikkael A Sekeres
Patients with higher-risk myelodysplastic syndromes (HR-MDS) have poor survival and are in need of more effective therapy options. Hypomethylating agents (HMAs) are the current standard of care and are being studied in combination with a nu...
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms [0.03%]
如何改善MDS治疗中的反应评估？改善MDS治疗模式中反应评估的策略
Rafael Bejar
Rafael Bejar
Evaluating response to treatment in MDS represents a major challenge due to its associated complexity and heterogeneity. Although response criteria have been proposed by the IWG and revised on several occasions, these criteria have limitati...
When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)? [0.03%]
成人急性淋巴细胞白血病(ALL)初始诱导治疗中的化疗何时会被替代？
Anjali Advani
Anjali Advani
The treatment of acute lymphoblastic leukemia (ALL) has changed significantly over the last decade. With the approval of novel antibody based therapies in the relapsed/refractory setting, many of these agents are starting to be used in the ...
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL [0.03%]
儿童急性淋巴细胞白血病治疗的长期并发症有哪些？以及如何缓解这些并发症？关于治愈性治疗在儿童急性淋巴细胞白血病中的长远影响的观点
Lia Gore
Lia Gore
Despite cure rates approaching 100% for some subsets of patients, survivors of childhood acute lymphoblastic leukemia (ALL) report a multitude of short- and long-term side effects. Indeed, the long-term complications of pediatric ALL treatm...
Nikolaos Spyrou,John E Levine,James L M Ferrara
Nikolaos Spyrou
Acute GVHD occurs in nearly 50% of patients receiving hematopoietic cell transplantation (HCT), and is the major driver of mortality. However, progress in the development of new acute GVHD therapeutics has been slow, in part due to heteroge...
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-19 [0.03%]
住院COVID-19患者中种族/民族，高甘油三酯血症，血栓和死亡率之间的相关性研究
Maya Rodriguez,Wen Dai,Hayley Lund et al.
Maya Rodriguez et al.
Reports of racial and ethnic disparities regarding both rates of infection of the SARS-CoV-2 virus and morbidity of the coronavirus disease-19 (COVID-19) contain profound differences depending on the population. Our previous study has shown...
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care [0.03%]
癌症患者中的SARS-CoV-2初次和突破性感染：对病人护理的启示
Lindsey Wang,William Wang,Rong Xu et al.
Lindsey Wang et al.
Initial reports of SARS-CoV-2 caused COVID-19 suggested that patients with malignant diseases were at increased risk for infection and its severe consequences. In order to provide early United States population-based assessments of SARS-CoV...
Jana Christian,Sophie Lanzkron,Rakhi P Naik
Jana Christian
Throughout the Coronavirus Disease 2019 (COVID-19) pandemic, understanding the effects of COVID-19 on persons with Sickle Cell Disease (SCD) and Sickle Cell Trait (SCT) has garnered interest. Patients with SCD diagnosed with COVID-19 utiliz...